Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02293837 · ClinicalTrials.gov registry record · Phase 2

Tocilizumab (TCZ) in New-onset Type 1 Diabetes

A Phase 2 study of Type 1 Diabetes Mellitus and T1D, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

Completed
Registry status
Phase 2
Development phase
136
Enrollment target
19
Study locations

NCT02293837 is a Phase 2 study of Type 1 Diabetes Mellitus and T1D that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 136 participants, roughly in line with the 139-participant average among 105 other Type 1 Diabetes Mellitus trials with a reported enrollment target. The trial reports 19 study locations across 16 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02293837, a Phase 2 study of Type 1 Diabetes Mellitus and T1D, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

COMPLETED
Registry status
Phase 2
Development phase
136 participants
Enrollment target
19
Study locations

Study Summary

Type 1 diabetes mellitus (T1DM) is an autoimmune disease. Based on previous research, study doctors think that giving medicines to affect the immune system soon after diabetes is diagnosed may stop, delay or decrease the destruction of beta cells, resulting in better glucose control. Researchers believe that tocilizumab could have some effect on the cells in the immune system that are thought to be involved in the development of type 1 diabetes. This study will test whether tocilizumab can help preserve or delay destruction of remaining beta cells in people recently diagnosed type 1 diabetes.

Conditions Studied

Type 1 Diabetes Mellitus T1D T1DM New-onset Type 1 Diabetes Mellitus

Interventions

  • DRUG Placebo
  • OTHER Standard of Care
  • DRUG Tocilizumab (TCZ)

Study Locations (19)

Florida

  • University of Florida - Gainesville
  • University of Miami: Diabetes Research Institute - Miami
  • University of South Florida: Diabetes Center - Tampa

California

  • University of California San Francisco - San Francisco
  • Stanford University - Stanford

Connecticut

  • Yale University School of Medicine: Diabetes Endocrinology Research Center - New Haven

Indiana

  • Indiana University Health - Riley Hospital for Children - Indianapolis

Iowa

  • University of Iowa - Iowa City

Massachusetts

  • Harvard University, Joslin Diabetes Center - Boston

Minnesota

  • University of Minnesota - Minneapolis

Missouri

  • Children's Mercy Hospital - Kansas City

Trial Details

FieldValue
Enrollment Target 136 participants
Start Date 2015-03-12
Est. Completion 2020-08-31
Phase Phase 2

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

2,006 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02293837

The ClinicalTrials.gov registry entry for NCT02293837 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 136 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 139-participant average among 105 other Type 1 Diabetes Mellitus trials with a reported enrollment target. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Type 1 Diabetes Mellitus appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT02293837 reports 19 study locations spanning 16 distinct geographic areas - top geographies include Florida, California, Connecticut.

Frequently Asked Questions

What is clinical trial NCT02293837 about?

NCT02293837 is a clinical study titled "Tocilizumab (TCZ) in New-onset Type 1 Diabetes". Type 1 diabetes mellitus (T1DM) is an autoimmune disease. Based on previous research, study doctors think that giving medicines to affect the immune system soon after diabetes is diagnosed may stop, delay or decrease the destruction of beta cells, resulting in better glucose control. Researchers be...

What is the current status of trial NCT02293837?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 136 participants. The study started on 2015-03-12. Estimated completion is 2020-08-31.

What conditions does trial NCT02293837 study?

This clinical trial studies the following conditions: Type 1 Diabetes Mellitus, T1D, T1DM, New-onset Type 1 Diabetes Mellitus.

What interventions are being tested in trial NCT02293837?

The interventions under investigation include: Placebo (DRUG), Standard of Care (OTHER), Tocilizumab (TCZ) (DRUG).

Who is sponsoring clinical trial NCT02293837?

This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02293837 being conducted?

This trial has 19 study locations across California, Connecticut, Florida, Indiana, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Type 1 Diabetes Mellitus

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Type 1 Diabetes Mellitus

All registered trials for this condition

T1D

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.